Waleria Healthtech to showcase its branded Shatavari root extract at SupplySide West 2024
Waleria’s plant-based, non-hormonal ingredient, the Shatavari root extract aspurūs, supports reducing menopausal symptoms.
Photo © AdobeStock.com/ insta_photos
Waleria Healthtech Private Limited has announced that it will be exhibiting at SupplySide West 2024, taking place on October 30-31st in Las Vegas, NV. The company focuses on women’s health solutions, namely a Shatavari root extract called aspurūs, which is its flagship ingredient. Shatavari root extract is traditionally known for its adaptogenic properties in Ayurvedic Medicine.
The company's branded Shatavari root has been subject to clinical research demonstrating its benefits. In a study published earlier this year in Cureus - Journal of Medical Sciences1, aspurūs was shown to help alleviate several symptoms of menopause including hot flashes and sleep quality. In the double-blind, multicenter, randomized controlled trial, 70 women received either the supplement or a placebo for eight weeks. Results showed that women taking the extract experienced a significant improvement in their quality of life, based on the Utian Quality of Life Scale, as well as significantly fewer symptoms, with reductions in night sweats, night flashes, anxiousness, fatigue, sleeplessness, mood swings, and urinary incontinence.
“We are excited to showcase aspurūs at SupplySide West and showcase its potential for improving the well-being of women experiencing symptoms during different stages of menopause,” said Komal Baldwa, founder of Waleria, in a press release. “Backed by clinical research for substantiated health benefits and now new foundational research for hormonal support, our traditional ayurvedic ingredient aligns with the growing demand for plant-based wellness products for innovative formulation in the women’s health category.”
To book a meeting at SuppySide West email: info@waleriahealthtech.com.
Reference
- Guidise, V.S.; Dasari, M.P.; Kuricheti, S.S.K. Efficacy and safety of shatavari root extract for the management of menopausal symptoms: A double-blind, multicenter, randomized controlled trial. Cureus. 2024. 16 (4), e57879. DOI: 10.7759/cureus.57879
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
